Abstract

You have accessJournal of UrologyCME1 Apr 2023MP51-04 REZŪM WATER VAPOUR THERAPY (REZŪM): IS IT SAFE TO CONTINUE ANTIPLATELET OR ANTICOAGULATION MEDICATION? Samuel Lee, Benjamin Lim, Thomas Chan, Shu Hui Neo, Alvin Low, Joshua Tung, Palaniappan Sundaram, Christopher Cheng, Lui Shiong Lee, and Yong Wei Lim Samuel LeeSamuel Lee More articles by this author , Benjamin LimBenjamin Lim More articles by this author , Thomas ChanThomas Chan More articles by this author , Shu Hui NeoShu Hui Neo More articles by this author , Alvin LowAlvin Low More articles by this author , Joshua TungJoshua Tung More articles by this author , Palaniappan SundaramPalaniappan Sundaram More articles by this author , Christopher ChengChristopher Cheng More articles by this author , Lui Shiong LeeLui Shiong Lee More articles by this author , and Yong Wei LimYong Wei Lim More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003299.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Rezūm water vapour therapy is a minimally invasive surgical technique for treatment of benign prostatic hyperplasia (BPH). Antiplatelets or anticoagulation medications (APAC) are usually suspended prior to Rezūm to reduce the risk of bleeding. Continuation of APAC reduces the risk of cardiovascular events for patients with advanced age and multiple comorbidities. This study aims to report the outcomes of Rezūm in patients who are continued on antiplatelet or anticoagulation medication. METHODS: All patients on antiplatelet or anticoagulation medication who had undergone Rezūm from November 2021 to August 2022 at a single centre in Singapore were followed up for 3 months. APAC were continued perioperatively. Outcomes were measured at 1 month, 2 month and 3 months postoperatively. RESULTS: N=15 men underwent Rezum while on APAC. 13 patients (87%) were on single antiplatelet therapy, 1 patient (7%) on novel anticoagulation therapy (NOAC): apixaban, and 1 patient (7%) on both NOAC and antiplatelet therapy: apixaban and clopidogrel. There was a sustained improvement in Qmax. 13 out of 15 patients (87%) had a successful removal of catheter. No complications of Clavien-Dindo classification greater than two at 30 days were observed. 2 patients (13%) required a manual bladder washout postoperatively. 1 patient (7%) was readmitted for a urinary tract infection and orchitis. 1 patient (7%) had a bladder neck contracture, who required an elective transurethral bladder neck incision after 2 months. CONCLUSIONS: This pilot study suggests that Rezum is a safe and effective option for patients who have bothersome lower urinary tract symptoms, and cannot stop anticoagulation or antiplatelet medication. Source of Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e693 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Samuel Lee More articles by this author Benjamin Lim More articles by this author Thomas Chan More articles by this author Shu Hui Neo More articles by this author Alvin Low More articles by this author Joshua Tung More articles by this author Palaniappan Sundaram More articles by this author Christopher Cheng More articles by this author Lui Shiong Lee More articles by this author Yong Wei Lim More articles by this author Expand All Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call